Matthew N. Jaffa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matthew N. Jaffa has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas A. Morris
Department of Neurology, Program in Trauma, University of Maryland School of Medicine, Baltimore, MD
4 shared publications - Aaron Taylor
Department of Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences, NY (R.M., A.T., D.W.).
1 shared publication - Adnan I. Qureshi
Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO 65212, USA
1 shared publication Alexandra S. Reynolds
Departments of Neurosurgery and Neurology, Mount Sinai Health System, New York, USA
1 shared publication- Alison S. Rondon
HARTFORD HEALTHCARE REHABILITATION NETWORK, HARTFORD, CT, USA
1 shared publication - Andrew W. Asimos
Department of Emergency Medicine, Neurosciences Institute, Wake Forest University School of Medicine, Advocate Health, Charlotte, NC 28203, USA
1 shared publication
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in Stroke
Association of Hemispheric Laterality With Neurosurgical Intervention in Intracerebral Hemorrhage: A Posthoc Bayesian Analysis of ATACH-2 and ERICH
BACKGROUND: Hemispheric laterality influences clinical management in stroke. Given the increasing enthusiasm for surgical management of intracerebral hemorrhage (ICH), we evaluated the association of hemispheric laterality with the likelihood of receiving neurosurgical intervention and subsequent 90-day functional outcomes. METHODS: This post hoc analysis included 3477 patients with supratentorial ICH from 2 prospective studies: the ATACH-2 trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage II), conducted at 110 sites in the United States, Japan, China, Taiwan, South Korea, and Germany (2011–2015), and the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage), conducted across 19 centers in the United States (2010–2015). The primary outcome was neurosurgical intervention (hematoma evacuation, decompressive craniectomy, or other craniotomy). Secondary outcomes included external ventricular drain placement, 90-day modified Rankin Scale score, and EuroQOL domains. Hierarchical Bayesian regression models estimating the association between ICH laterality and outcomes were adjusted for age, admission Glasgow Coma Scale, ICH location, ICH volume, and intraventricular hemorrhage. RESULTS: Of 3477 patients, right hemispheric ICH was associated with a higher likelihood of receiving neurosurgical intervention (adjusted odds ratio, 1.65 [95% credible interval, 1.28–2.14]) and external ventricular drain placement (adjusted odds ratio, 1.22 [95% credible interval, 1.04–1.44]) compared with left hemispheric ICH. This association was directionally consistent across ICH locations, study cohorts, and prior specifications. Despite the lower rates of surgical intervention in left hemispheric ICH, there was no meaningful difference in 90-day functional outcomes in patients with left and right hemispheric ICH. CONCLUSIONS: Right hemispheric ICH is associated with a higher likelihood of neurosurgical intervention compared with left hemispheric ICH, though 90-day functional outcomes remain similar between groups. Although these findings highlight a potential laterality-associated variation in neurosurgical intervention, residual confounding from unmeasured anatomic severity and family preferences cannot be excluded. Prospective studies are needed to delineate the explicit clinical and prognostic drivers of surgical decision-making to optimize treatment allocation in ICH. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01176565 and NCT01202864.
- 22 October 2026
- Published by Wolters Kluwer Health in Stroke
Association of Hemispheric Laterality With Neurosurgical Intervention in Intracerebral Hemorrhage: A Posthoc Bayesian Analysis of ATACH-2 and ERICH
BACKGROUND: Hemispheric laterality influences clinical management in stroke. Given the increasing enthusiasm for surgical management of intracerebral hemorrhage (ICH), we evaluated the association of hemispheric laterality with the likelihood of receiving neurosurgical intervention and subsequent 90-day functional outcomes. METHODS: This post hoc analysis included 3477 patients with supratentorial ICH from 2 prospective studies: the ATACH-2 trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage II), conducted at 110 sites in the United States, Japan, China, Taiwan, South Korea, and Germany (2011–2015), and the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage), conducted across 19 centers in the United States (2010–2015). The primary outcome was neurosurgical intervention (hematoma evacuation, decompressive craniectomy, or other craniotomy). Secondary outcomes included external ventricular drain placement, 90-day modified Rankin Scale score, and EuroQOL domains. Hierarchical Bayesian regression models estimating the association between ICH laterality and outcomes were adjusted for age, admission Glasgow Coma Scale, ICH location, ICH volume, and intraventricular hemorrhage. RESULTS: Of 3477 patients, right hemispheric ICH was associated with a higher likelihood of receiving neurosurgical intervention (adjusted odds ratio, 1.65 [95% credible interval, 1.28–2.14]) and external ventricular drain placement (adjusted odds ratio, 1.22 [95% credible interval, 1.04–1.44]) compared with left hemispheric ICH. This association was directionally consistent across ICH locations, study cohorts, and prior specifications. Despite the lower rates of surgical intervention in left hemispheric ICH, there was no meaningful difference in 90-day functional outcomes in patients with left and right hemispheric ICH. CONCLUSIONS: Right hemispheric ICH is associated with a higher likelihood of neurosurgical intervention compared with left hemispheric ICH, though 90-day functional outcomes remain similar between groups. Although these findings highlight a potential laterality-associated variation in neurosurgical intervention, residual confounding from unmeasured anatomic severity and family preferences cannot be excluded. Prospective studies are needed to delineate the explicit clinical and prognostic drivers of surgical decision-making to optimize treatment allocation in ICH. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01176565 and NCT01202864.
- 15 October 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Systematic CRS-R-based Evaluation of Disorders of Consciousness in the ICU
Evaluation and prognostication following disorders of consciousness (DoC) is a complex task with significant implications. The Coma Recovery Scale, Revised (CRS-R) is a standardized neurobehavioral assessment that enables clinicians to accurately differentiate between coma, unresponsive wakefulness syndrome (UWS), minimally conscious state (MCS), and emergence from MCS. Newly described paradigms present ambitious programs utilizing multidisciplinary clinical teams working in sync with new technologies to optimize and improve a systematic approach to prognostication following DoC. We developed a DoC program at a level 1 trauma and comprehensive stroke center to optimize diagnosis and management of DoC patients. Through an iterative approach our program developed a DoC team to standardize the use of the CRS-R for patients with DoC and formalize a training program for its use. In addition, a formal DoC consult group was created incorporating the neurocritical care faculty to provide expertise and to assist with collaborative decision making. We detail our program’s development, barriers, outcomes, and future directions. The core features of this novel clinical paradigm—structured assessment, interdisciplinary collaboration, and iterative re-evaluation—can be adapted to more resource-limited settings to improve outcomes, communication, and the consistency and transparency of prognostication in disorders of consciousness.
- 15 October 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Systematic CRS-R-based Evaluation of Disorders of Consciousness in the ICU
Evaluation and prognostication following disorders of consciousness (DoC) is a complex task with significant implications. The Coma Recovery Scale, Revised (CRS-R) is a standardized neurobehavioral assessment that enables clinicians to accurately differentiate between coma, unresponsive wakefulness syndrome (UWS), minimally conscious state (MCS), and emergence from MCS. Newly described paradigms present ambitious programs utilizing multidisciplinary clinical teams working in sync with new technologies to optimize and improve a systematic approach to prognostication following DoC. We developed a DoC program at a level 1 trauma and comprehensive stroke center to optimize diagnosis and management of DoC patients. Through an iterative approach our program developed a DoC team to standardize the use of the CRS-R for patients with DoC and formalize a training program for its use. In addition, a formal DoC consult group was created incorporating the neurocritical care faculty to provide expertise and to assist with collaborative decision making. We detail our program’s development, barriers, outcomes, and future directions. The core features of this novel clinical paradigm—structured assessment, interdisciplinary collaboration, and iterative re-evaluation—can be adapted to more resource-limited settings to improve outcomes, communication, and the consistency and transparency of prognostication in disorders of consciousness.
- Open Access
- 5 November 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (11) , e1342
NeuroRecovery Clinics: A Survey to Understand the Current Landscape and Opinions of Post-NeuroICU Clinics
OBJECTIVES: Survival following severe acute neurologic injury (SANI) is increasing. The complexities of caring for these patients are vast and gaps have been highlighted in post-acute care follow-up. While the development of post-ICU follow-up clinics have been increasing in popularity there is limited literature describing the landscape of post-neuroICU/NeuroRecovery clinics. We sought to describe the current landscape and identify benefits and barriers to clinic development in the United States. DESIGN: We developed a 19-question cross-sectional survey study. SETTING AND SUBJECTS: The survey was disseminated to clinicians working in neurocritical care units throughout the United States and open for completion from August 2023 to December 2023. Responses were characterized by descriptive statistics. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Two hundred eighteen unique individuals responded to our survey. Post-neuroICU and/or NeuroRecovery clinics were uncommon and operational at only 69 of 215 respondents’ institutions (32.1%). Forty-two percent reported an interest in engaging with a post-neuroICU clinic and an additional 39% showed interest but had identified other obligations preventing participation. Among the identified potential benefits of a clinic for survivors of SANI mitigating gaps in care, identifying differences between predicted and actual outcome, and reassessment of communication/prognosis ranked highest. CONCLUSIONS: Few post-neuroICU/NeuroRecovery clinics exist in the United States but interest in participating in this aspect of care is common within the neurocritical care community. The identification of gaps in care, obstacles to continued recovery, and potential to adjudicate differences between actual and predicted outcomes ranked among the most important potential benefits for extending the current neurocritical care paradigm to the clinic setting.
- 5 November 2025
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (11) , e1342
Open AccessNeuroRecovery Clinics: A Survey to Understand the Current Landscape and Opinions of Post-NeuroICU Clinics
OBJECTIVES: Survival following severe acute neurologic injury (SANI) is increasing. The complexities of caring for these patients are vast and gaps have been highlighted in post-acute care follow-up. While the development of post-ICU follow-up clinics have been increasing in popularity there is limited literature describing the landscape of post-neuroICU/NeuroRecovery clinics. We sought to describe the current landscape and identify benefits and barriers to clinic development in the United States. DESIGN: We developed a 19-question cross-sectional survey study. SETTING AND SUBJECTS: The survey was disseminated to clinicians working in neurocritical care units throughout the United States and open for completion from August 2023 to December 2023. Responses were characterized by descriptive statistics. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Two hundred eighteen unique individuals responded to our survey. Post-neuroICU and/or NeuroRecovery clinics were uncommon and operational at only 69 of 215 respondents’ institutions (32.1%). Forty-two percent reported an interest in engaging with a post-neuroICU clinic and an additional 39% showed interest but had identified other obligations preventing participation. Among the identified potential benefits of a clinic for survivors of SANI mitigating gaps in care, identifying differences between predicted and actual outcome, and reassessment of communication/prognosis ranked highest. CONCLUSIONS: Few post-neuroICU/NeuroRecovery clinics exist in the United States but interest in participating in this aspect of care is common within the neurocritical care community. The identification of gaps in care, obstacles to continued recovery, and potential to adjudicate differences between actual and predicted outcomes ranked among the most important potential benefits for extending the current neurocritical care paradigm to the clinic setting.
- 18 August 2025
- Published by Springer Nature in Neurocritical Care
- p. 1-3
Palliative Care in the Neurocritical Care Unit: Increasing Primary Palliative Care Skills
- 18 August 2025
- Published by Springer Nature in Neurocritical Care
- p. 1-3
Palliative Care in the Neurocritical Care Unit: Increasing Primary Palliative Care Skills
- 26 September 2023
- Published by Springer Nature in Neurocritical Care
- Vol. 39 (3) , 742-743
Response to “Some Contributions on Standardized Education for Brain Death Determination”
- 26 September 2023
- Published by Springer Nature in Neurocritical Care
- Vol. 39 (3) , 742-743
Response to “Some Contributions on Standardized Education for Brain Death Determination”
- 9 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (19) , 891-892
Maximal Care After Intracerebral Hemorrhage
- 9 May 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (19) , 891-892
Maximal Care After Intracerebral Hemorrhage
- 28 April 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 13 (3) , 236-242
Steroids Provide Temporary Improvement of Refractory Pain Following Subarachnoid Hemorrhage
Introduction: Evidence for optimal analgesia following subarachnoid hemorrhage (SAH) is limited. Steroid therapy for pain refractory to standard regimens is common despite lack of evidence for its efficacy. We sought to determine if steroids reduced pain or utilization of other analgesics when given for refractory headache following SAH. Methods: We performed a retrospective within-subjects cohort study of SAH patients who received steroids for refractory headache. We compared daily pain scores, total daily opioid, and acetaminophen doses before, during, and after steroids. Repeated measures were analyzed with a multivariable general linear model and generalized estimating equations. Results: Included 52 patients treated with dexamethasone following SAH, of whom 11 received a second course, increasing total to 63 treatment epochs. Mean pain score on the first day of therapy was 7.92 (standard error of the mean [SEM] .37) and decreased to 6.68 (SEM .36) on the second day before quickly returning to baseline levels, 7.36 (SEM .33), following completion of treatment. Total daily analgesics mirrored this trend. Mean total opioid and acetaminophen doses on days one and two and two days after treatment were 47.83mg (SEM 6.22) and 1848mg (SEM 170.66), 34.24mg (SEM 5.12) and 1809mg (SEM 150.28), and 46.38mg (SEM 11.64) and 1833mg (SEM 174.23), respectively. Response to therapy was associated with older age, decreasing acetaminophen dosing, and longer duration of steroids. Hyperglycemia and sleep disturbance/delirium effected 28.6% and 55.6% of cases, respectively. Conclusion: Steroid therapy for refractory pain in SAH patients may have modest, transient effects in select patients.
- 28 April 2023
- Published by SAGE Publications in The Neurohospitalist
- Vol. 13 (3) , 236-242
Steroids Provide Temporary Improvement of Refractory Pain Following Subarachnoid Hemorrhage
Introduction: Evidence for optimal analgesia following subarachnoid hemorrhage (SAH) is limited. Steroid therapy for pain refractory to standard regimens is common despite lack of evidence for its efficacy. We sought to determine if steroids reduced pain or utilization of other analgesics when given for refractory headache following SAH. Methods: We performed a retrospective within-subjects cohort study of SAH patients who received steroids for refractory headache. We compared daily pain scores, total daily opioid, and acetaminophen doses before, during, and after steroids. Repeated measures were analyzed with a multivariable general linear model and generalized estimating equations. Results: Included 52 patients treated with dexamethasone following SAH, of whom 11 received a second course, increasing total to 63 treatment epochs. Mean pain score on the first day of therapy was 7.92 (standard error of the mean [SEM] .37) and decreased to 6.68 (SEM .36) on the second day before quickly returning to baseline levels, 7.36 (SEM .33), following completion of treatment. Total daily analgesics mirrored this trend. Mean total opioid and acetaminophen doses on days one and two and two days after treatment were 47.83mg (SEM 6.22) and 1848mg (SEM 170.66), 34.24mg (SEM 5.12) and 1809mg (SEM 150.28), and 46.38mg (SEM 11.64) and 1833mg (SEM 174.23), respectively. Response to therapy was associated with older age, decreasing acetaminophen dosing, and longer duration of steroids. Hyperglycemia and sleep disturbance/delirium effected 28.6% and 55.6% of cases, respectively. Conclusion: Steroid therapy for refractory pain in SAH patients may have modest, transient effects in select patients.
- Open Access
- 22 April 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 165
Intracranial fungal Cladophialophora bantiana infection in a nonimmunocompromised patient: A case report and review of the literature
Background: Cladophialophora bantiana is a dematiaceous fungus that rarely infects the central nervous system (CNS). It is associated with a mortality rate of over 70% despite treatment. Case Description: An 81-year-old female with a remote history of renal cell carcinoma presented with progressive headache and an expressive aphasia for 3 days. Computed tomography imaging revealed a left frontotemporal mass with surrounding vasogenic edema. A left frontotemporal craniotomy was performed and cultures revealed C. bantiana. The initial management with IV voriconazole was unsuccessful and the patient had a recurrence of the cranial infection and developed pulmonary abscesses. Following the addition of oral flucytosine, the patient showed a significant improvement with a complete radiographic resolution of both the cranial and pulmonary lesions. Conclusion: C. bantiana involving the CNS is a rare and often fatal disease. Surgical management along with standard antifungal treatment may not provide definitive therapy. The addition of flucytosine to IV voriconazole resulted in a positive outcome for this patient who is alive, living independently 1 year from the original diagnosis. In this rare fungal infection, standard antifungal treatment may not provide adequate coverage and the utilization of additional therapy may be required.
- 22 April 2022
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 13, 165
Open AccessIntracranial fungal Cladophialophora bantiana infection in a nonimmunocompromised patient: A case report and review of the literature
Background: Cladophialophora bantiana is a dematiaceous fungus that rarely infects the central nervous system (CNS). It is associated with a mortality rate of over 70% despite treatment. Case Description: An 81-year-old female with a remote history of renal cell carcinoma presented with progressive headache and an expressive aphasia for 3 days. Computed tomography imaging revealed a left frontotemporal mass with surrounding vasogenic edema. A left frontotemporal craniotomy was performed and cultures revealed C. bantiana. The initial management with IV voriconazole was unsuccessful and the patient had a recurrence of the cranial infection and developed pulmonary abscesses. Following the addition of oral flucytosine, the patient showed a significant improvement with a complete radiographic resolution of both the cranial and pulmonary lesions. Conclusion: C. bantiana involving the CNS is a rare and often fatal disease. Surgical management along with standard antifungal treatment may not provide definitive therapy. The addition of flucytosine to IV voriconazole resulted in a positive outcome for this patient who is alive, living independently 1 year from the original diagnosis. In this rare fungal infection, standard antifungal treatment may not provide adequate coverage and the utilization of additional therapy may be required.
- 21 April 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (2) , 247-254
Neurologic Outcomes After Extracorporeal Cardiopulmonary Resuscitation: Recent Experience at a Single High-Volume Center
Extracorporeal cardiopulmonary resuscitation (ECPR)—veno-arterial extracorporeal membrane oxygenation (ECMO) for refractory cardiac arrest—has grown rapidly, but its widespread adoption has been limited by frequent neurologic complications. With individual centers developing best practices, utilization may be increasing with an uncertain effect on outcomes. This study describes the recent ECPR experience at the University of Maryland Medical Center from 2016 through 2018, with attention to neurologic outcomes and predictors thereof. The primary outcome was dichotomized Cerebral Performance Category (≤2) at hospital discharge; secondary outcomes included rates of specific neurologic complications. From 429 ECMO runs over 3 years, 57 ECPR patients were identified, representing an increase in ECPR utilization compared with 41 cases over the previous 6 years. Fifty-two (91%) suffered in-hospital cardiac arrest, and 36 (63%) had an initial nonshockable rhythm. Median low-flow time was 31 minutes. Overall, 26 (46%) survived hospitalization and 23 (88% of survivors, 40% overall) had a favorable discharge outcome. Factors independently associated with good neurologic outcome included lower peak lactate, initial shockable rhythm, and higher initial ECMO mean arterial pressure. Neurologic complications occurred in 18 patients (32%), including brain death in 6 (11%), hypoxic-ischemic brain injury in 11 (19%), ischemic stroke in 6 (11%), intracerebral hemorrhage in 1 (2%), and seizure in 4 (7%). We conclude that good neurologic outcomes are possible for well-selected ECPR patients in a high-volume program with increasing utilization and evolving practices. Markers of adequate peri-resuscitation tissue perfusion were associated with better outcomes, suggesting their importance in neuroprognostication.
- 21 April 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (2) , 247-254
Neurologic Outcomes After Extracorporeal Cardiopulmonary Resuscitation: Recent Experience at a Single High-Volume Center
Extracorporeal cardiopulmonary resuscitation (ECPR)—veno-arterial extracorporeal membrane oxygenation (ECMO) for refractory cardiac arrest—has grown rapidly, but its widespread adoption has been limited by frequent neurologic complications. With individual centers developing best practices, utilization may be increasing with an uncertain effect on outcomes. This study describes the recent ECPR experience at the University of Maryland Medical Center from 2016 through 2018, with attention to neurologic outcomes and predictors thereof. The primary outcome was dichotomized Cerebral Performance Category (≤2) at hospital discharge; secondary outcomes included rates of specific neurologic complications. From 429 ECMO runs over 3 years, 57 ECPR patients were identified, representing an increase in ECPR utilization compared with 41 cases over the previous 6 years. Fifty-two (91%) suffered in-hospital cardiac arrest, and 36 (63%) had an initial nonshockable rhythm. Median low-flow time was 31 minutes. Overall, 26 (46%) survived hospitalization and 23 (88% of survivors, 40% overall) had a favorable discharge outcome. Factors independently associated with good neurologic outcome included lower peak lactate, initial shockable rhythm, and higher initial ECMO mean arterial pressure. Neurologic complications occurred in 18 patients (32%), including brain death in 6 (11%), hypoxic-ischemic brain injury in 11 (19%), ischemic stroke in 6 (11%), intracerebral hemorrhage in 1 (2%), and seizure in 4 (7%). We conclude that good neurologic outcomes are possible for well-selected ECPR patients in a high-volume program with increasing utilization and evolving practices. Markers of adequate peri-resuscitation tissue perfusion were associated with better outcomes, suggesting their importance in neuroprognostication.